Antiseptics and the Ocular Surface: In Vitro Antimicrobial Activity and Effects on Conjunctival and Corneal Epithelial Cells of a New Liposomal Ocular Spray Containing Biosecur
Antiseptic
Biosecur
Citrus Extract
Conjunctival Epithelial Cells
Corneal Epithelial Cells
Flavonoids
Liposome
Oftasecur
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
22
01
2022
accepted:
23
02
2022
pubmed:
15
3
2022
medline:
15
3
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
The study aimed to evaluate the in vitro antimicrobial activity of a new liposomal ocular spray containing the antiseptic Biosecur Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) of Oftasecur against Candida albicans and Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains, were determined. Human corneal and conjunctival epithelial cells in vitro were incubated for 10 and 30 min with Oftasecur or its components. The cytotoxicity was assessed through the release of cytoplasmic enzyme lactate dehydrogenase (LDH) into the medium; the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to evaluate the cell viability. Oftasecur was active at dilutions ranging from 1:2 to 1:16 and it displayed bactericidal and fungicidal effect against all assayed microorganisms. Most of the reduction of Staphylococcus epidermidis vitality (65%) occurred within the first minute of exposure. The cytotoxicity of Oftasecur was similar to its vehicle, and the cell viability was significantly reduced only by Oftasecur in its undiluted form. Conversely, Biosecur induced a significant cytotoxicity in all the experiments. Oftasecur showed a rapid and wide-spectrum antibacterial activity, with an optimal in vitro tolerability profile.
Identifiants
pubmed: 35284982
doi: 10.1007/s40123-022-00492-0
pii: 10.1007/s40123-022-00492-0
pmc: PMC9114213
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1067-1077Informations de copyright
© 2022. The Author(s).
Références
Curr Opin Lipidol. 2000 Feb;11(1):43-7
pubmed: 10750693
J Drug Deliv. 2011;2011:863734
pubmed: 21490757
Curr Opin Ophthalmol. 2017 Jan;28(1):67-72
pubmed: 27661662
Colloids Surf B Biointerfaces. 2016 Sep 1;145:241-250
pubmed: 27187188
Open Microbiol J. 2013 Nov 08;7:130-4
pubmed: 24302976
PLoS One. 2018 Oct 18;13(10):e0205814
pubmed: 30335799
Eye (Lond). 2022 Jan;36(1):160-166
pubmed: 33654316
Curr Opin Ophthalmol. 2018 Jan;29(1):19-32
pubmed: 28984794
Am J Ophthalmol. 1996 Jul;122(1):1-17
pubmed: 8659579
J Appl Microbiol. 2007 Dec;103(6):2056-64
pubmed: 18045389
Int J Food Microbiol. 2004 Aug 1;94(3):223-53
pubmed: 15246235
Pharmaceutics. 2021 Dec 05;13(12):
pubmed: 34959374
Surv Ophthalmol. 2018 Nov - Dec;63(6):862-868
pubmed: 29778494
Pharmaceutics. 2021 Oct 15;13(10):
pubmed: 34683990
Jpn J Ophthalmol. 2014 Nov;58(6):522-7
pubmed: 25230910
Ophthalmology. 2011 Oct;118(10):2035-40
pubmed: 21856006
Ophthalmic Surg Lasers Imaging Retina. 2014 Mar-Apr;45(2):143-9
pubmed: 24635156
Ophthalmol Ther. 2021 Dec;10(4):1025-1032
pubmed: 34495493
BMC Ophthalmol. 2017 Nov 25;17(1):212
pubmed: 29178851
Nanomedicine. 2009 Dec;5(4):394-401
pubmed: 19341814
Exp Eye Res. 2020 Dec;201:108269
pubmed: 32980315
Am J Ophthalmol. 2017 Apr;176:244-253
pubmed: 27984024